What's new

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Feb 24, 2025 - 10:11
 0
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive
Read More

Tags:

Previous Article

Maximise your retention and profits with EMaC

Next Article

Drones are the next chapter in US-India’s defense partnership

Related Posts

Minutes of the CAT meeting 22-24 January 2025

Feb 27, 2025  0

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 25, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0062/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 21, 2025  0